Eli Lilly: Growth Hype Pushes Stock 17% Past Fair Value
By stockpickr AI | March 3, 2026 | 10 min read
Investment Summary
Eli Lilly (LLY) in the Pharmaceuticals sector appears significantly overvalued based on the DCF analysis, driven by massive recent growth expectations.
Investment Recommendation
Hold
Fair Value: $610.50
Current Price: $734.41
Upside/Downside: -16.87%
The DCF model suggests a fair value significantly lower than the current market price, indicating the stock is substantially overvalued based on conservative growth assumptions. While the business outlook is excellent, the current price already reflects ultra-aggressive, near-term growth projections, leaving limited margin of safety.
Key Metrics
- Market Cap: $923.35B
- P/E Ratio: 113.48x
- Forward P/E: 48.78x
- Revenue Growth (YoY): 26.10%
- Net Margin: 22.51%
- ROE: 33.60%
- Debt/Equity: 0.37
- Dividend Yield: 0.63%
Strengths
- Dominant position in the rapidly expanding obesity/diabetes drug market with Mounjaro/Zepbound (Tirzepatide).
- Exceptional recent revenue growth, reporting Q1 2024 revenue of $9.34 billion, up 26% YoY.
- Strong profitability demonstrated by a high Net Margin of 22.51% on a trailing basis.
- Robust balance sheet with significant cash reserves providing flexibility for R&D and acquisitions.
Risk Factors
- The current valuation (P/E > 113x) heavily prices in flawless execution and continued high growth rates.
- Exclusivity risk and intense competition from Novo Nordisk (Wegovy/Ozempic) and potential entrants.
- Regulatory and patent expiry risks associated with key revenue drivers down the line.